Microneedling for Burns

Phase-Based Progress Estimates
Villa Medica Rehabilitation Hospital, Montréal, Canada
Burns+2 More
Microneedling - Procedure
Any Age
All Sexes
What conditions do you have?

Study Summary

Approximately 33 to 91% of severe burn victims will develop hypertrophic scars. Hypertrophic scars are defined as erythematous (red), raised and rigid scars that can cause pain and itching, among other things. They cause psychological distress and affect the quality of life of burn victims. Microneedling is a technique that uses an electrical device to create hundreds of microchannels that penetrate the skin layers. This study is interested in determining the effectiveness of microneedling in improving the pliability, thickness and erythema of hypertrophic scars. Each scar will receive up to 5 ACS-pen treatments followed by the application of cortisone (triamcinolone acetonide). Knowing that microneedling increases the absorption of products applied to the skin by about 80%, it is logical to think that creating these channels to the dermis and applying cortisone afterwards would have a beneficial effect on the hypertrophic scars of these patients.

Eligible Conditions

  • Burns
  • Burn Scars

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: Baseline, before treatments #3, #4 and #5, post 6 weeks and 12 weeks

Week 12
Patient reported effectiveness of intervention
Week 12
Cutometer Skin Elasticity Changes
Skin Erythema Changes
Skin Thickness Changes

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Control scar
1 of 2
Microneedling treated scar
1 of 2
Active Control
Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Microneedling · No Placebo Group · N/A

Microneedling treated scar
Experimental Group · 1 Intervention: Microneedling · Intervention Types: Procedure
Control scarNoIntervention Group · 1 Intervention: Control scar · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, before treatments #3, #4 and #5, post 6 weeks and 12 weeks
Closest Location: Villa Medica Rehabilitation Hospital · Montréal, Canada
2008First Recorded Clinical Trial
3 TrialsResearching Burns
1 CompletedClinical Trials

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
319 Previous Clinical Trials
112,213 Total Patients Enrolled
7 Trials studying Burns
430 Patients Enrolled for Burns

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a negative pregnancy test if you are 16 years of age or older.
You have at least 2 HSc that meet the clinical criteria for HSc.
You provide written informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.